New and Noteworthy in June

Upcoming Appearances

June 8^th: David Rind, MD, MSc, ICER’s Chief Medical Officer, will be a panelist during a discussion on “Exploring How Sentinel Infrastructure Could Generate Real World Evidence on PCSK9 Inhibitors” at a conference titled Building a National Resource for Evidence Generation hosted by the Duke-Margolis Center for Health Policy in Washington, DC.

June 12^th: Steve Pearson, MD, MSc, ICER’s President, will participate in a panel during the Massachusetts Association of Health Plans’ policy forum, Can Advances in Medicine Coexist with Cost Containment – How are States Addressing Prescription Drug Costs?, to be held in Boston, MA.

June 14^th: Dan Ollendorf, PhD, ICER’s Chief Scientific Officer, will participate in a Canadian Patented Medicines Prices Review Board Fair Pricing Initiative Workgroup Meeting in Ottawa, ON, Canada.

June 17^th-21^st: Steve Pearson will participate in Health Technology Assessment International’s annual meeting in Rome, Italy.

June 21^st: Sarah Emond, MPP, ICER’s Executive Vice President and Chief Operating Officer, will be a panelist during a breakfast session, titled Tackling the Drug Price Problem: A Town Hall Debate, hosted by FierceBiotech at the BIO International Convention in San Diego, CA.

June 22^nd– 23^rd: Dan Ollendorf will be a panelist at a conference titled “Ensuring Safety, Efficacy and Access to Medical Products in the Age of Global Deregulation” at Yale University in New Haven, CT.

June 28^th: Steve Pearson will participate in a Canadian Precision Medicine Payment Meeting.

Key Dates

June 8^th: Atopic dermatitis Final Evidence Report and Meeting Summary posted
June 9^th: Revised Scoping Document for tardive dyskinesia report posted
June 16^th: Osteoporosis Evidence Report posted
June 28^th: Abuse-deterrent opioids Evidence Report posted
June 30^th: Public meeting of CTAF on treatments for osteoporosis